Sanofi: Clinical trial disclosure (Lyxumia) and (Zaltrap) — AUTH/2900/11/16 & AUTH/2910/11/16 | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2900/11/16 and AUTH/2910/11/16
Complainant	Director
Company	Sanofi
Issue	Clinical trial disclosure (Lyxumia) and (Zaltrap)
Complaint received	06 December 2016
Completed	13 March 2017
Outcome	No breach; outwith the scope of the Code
Clauses cited	Not stated
Sanctions	None stated (no breach)
Additional sanctions	Not stated

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

The PMCPA Director raised a complaint against Sanofi concerning clinical trial disclosure relating to Lyxumia and Zaltrap.
The matter was considered under case numbers AUTH/2900/11/16 and AUTH/2910/11/16.
Complaint received: 06 December 2016.

⚖️

⌄

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →